TARGETED SENOLYTIC STRATEGIES
IN THE NEWS

Rubedo listed among top senolytic companies in Nature Biotechnology

Send in the senolytics

Despite early failures in the clinic, the idea of anti-aging therapies that purge the body of dying cells is gaining traction with a raft of startups now focused on senescence.

Valuable review describing the emerging field of therapeutic development targeting senescence biology to treat age-related conditions.

Rubedo at Longevity Therapeutics Conference 2021

Join us at LT2021. Rubedo will be contributing with a lecture and a round table.

 

Rubedo Life Sciences CEO, Dr. Marco Quarta, will join the Panel Discussion titled

A Therapeutic Revolution Against Aging – Bridging the Gaps & Opportunities

Moreover, Dr. Quarta will give a lecture on Higher selectivity and safety of Targeted Senolytcs

Internship Opportunities in 2021 at Rubedo

Salaried internship opportunities at Rubedo Life Sciences for 2021-2022

9 month internship – CalPoly CIRM Master Program for Regenerative Medicine

 

Summer Internship – SENS Research Foundation Program

Ending Age-Related Diseases Conference 2020

Rubedo Life Sciences presents results from its strategy of engineered small molecules to target senescence cells in chronic diseases at Ending Age-Related Diseases Conference

Longevity Therapeutics 2020

Rubedo Life Sciences CEO, Dr. Marco Quarta presents the novel targeted senolytic program based on Rubedo engineered small molecules

Targeting Chronic Diseases Through Geroscience

Rubedo Life Sciences is represented by CEO, Dr. Marco Quarta, at the National Institute of Aging of the National Institute of Health (NIA-NIH) Geroscience Summit titled: “Targeting Chronic Diseases Through Geroscience

Silicon Valley, CA, USA

Copyright 2020 by Rubedo Life Sciences, inc